Bridging non-human primate correlates of protection to reassess theAnthrax Vaccine Adsorbed booster schedule in humans

摘要

Anthrax Vaccine Adsorbed (AVA, BioThrax®) is approved for use in humans as a priming series of 3 intramuscular (i.m.) injections (0, 1, 6 months; 3-IM) with boosters at 12 and 18 months, and annually thereafter for those at continued risk of infection. A reduction in AVA booster frequency would lessen the burden of vaccination, reduce the cumulative frequency of vaccine associated adverse events and potentially expand vaccine coverage by requiring fewer doses per schedule. Because human inhalation anthrax studies are neither feasible nor ethical, AVA efficacy estimates are determined using cross-species bridging of immune correlates of protection (COP) identified in animal models. We have previously reported that the AVA 3-IM priming series provided high levels of protection in non-human primates (NHP) against inhalation anthrax for up to 4 years after the first vaccination. Penalized logistic regressions of those NHP immunological data identified that anti-protective antigen (anti-PA) IgG concentration measured just prior to infectious challenge was the most accurate single COP.In the present analysis, cross-species logistic regression models of this COP were used to predict probability of survival during a 43 month study in humans receiving the current 3-dose priming and 4 boosters (12, 18, 30 and 42months; 7-IM) and reduced schedules with boosters at months 18 and 42 only(5-IM), or at month 42 only (4-IM). All models predicted high survivalprobabilities for the reduced schedules from 7 to 43 months. The predictedsurvival probabilities for the reduced schedules were 86.8% (4-IM) and 95.8%(5-IM) at month 42 when antibody levels were lowest. The data indicated that4-IM and 5-IM are both viable alternatives to the current AVA pre-exposureprophylaxis schedule.